GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Price-to-Free-Cash-Flow

BMKDF (Biomark Diagnostics) Price-to-Free-Cash-Flow : N/A (As of Dec. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics Price-to-Free-Cash-Flow?

As of today (2024-12-12), Biomark Diagnostics's share price is $0.1515. Biomark Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.01. Hence, Biomark Diagnostics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Biomark Diagnostics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Biomark Diagnostics's highest Price-to-Free-Cash-Flow Ratio was 83.33. The lowest was 51.67. And the median was 63.33.

BMKDF's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 27.66
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Biomark Diagnostics's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -24.60% per year.

During the past 11 years, Biomark Diagnostics's highest 3-Year average Free Cash Flow per Share Growth Rate was 32.90% per year. The lowest was -58.70% per year. And the median was -2.90% per year.


Biomark Diagnostics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Biomark Diagnostics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Price-to-Free-Cash-Flow Chart

Biomark Diagnostics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomark Diagnostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomark Diagnostics's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Biomark Diagnostics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Price-to-Free-Cash-Flow falls into.



Biomark Diagnostics Price-to-Free-Cash-Flow Calculation

Biomark Diagnostics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.1515/-0.01
=N/A

Biomark Diagnostics's Share Price of today is $0.1515.
Biomark Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Biomark Diagnostics  (OTCPK:BMKDF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Biomark Diagnostics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.

Biomark Diagnostics Headlines

No Headlines